Compare
Cadrenal Therapeutics, Inc. vs Immunic, Inc. vs Rein Therapeutics, Inc. vs Nuvectis Pharma, Inc.
| Latest fiscal year | Cadrenal Therapeutics, Inc. CVKD | Immunic, Inc. IMUX | Rein Therapeutics, Inc. RNTX | Nuvectis Pharma, Inc. NVCT |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | $0 | n/a |
| Revenue growth (YoY) | n/a | n/a | n/a | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | n/a | n/a |
| Net margin | n/a | n/a | n/a | n/a |
| Net income | -$13.24M | -$97.17M | -$49.87M | -$26.44M |
| EPS (Diluted) | -$6.64 | -$0.62 | -$1.96 | -$1.32 |
| Operating cash flow | -$12.60M | -$85.81M | -$19.36M | -$16.01M |
| Free cash flow | -$12.61M | -$85.97M | n/a | n/a |
| Cash & equivalents | $4.01M | $15.48M | $3.21M | $31.63M |
| Total assets | $4.33M | $24.05M | $24.16M | $31.71M |
| Total liabilities | $1.59M | $30.73M | $7.24M | $13.30M |
| Shareholders' equity | $2.74M | -$6.67M | $16.92M | $18.41M |
| Return on year-end equity | -483.3% | n/a | -294.8% | -143.6% |
| Shares outstanding | 2.34M | 90.15M | 27.55M | 25.68M |
Revenue, most recent five fiscal years
| Fiscal year | Cadrenal Therapeutics, Inc. | Immunic, Inc. | Rein Therapeutics, Inc. | Nuvectis Pharma, Inc. |
|---|---|---|---|---|
| Latest | n/a | n/a | $0 Ended 2025-12-31 | n/a |
| 1 year earlier | n/a | n/a | $0 Ended 2024-12-31 | n/a |
| 2 years earlier | n/a | n/a | $0 Ended 2023-12-31 | n/a |
| 3 years earlier | n/a | n/a | $0 Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | n/a | $0 Ended 2021-12-31 | n/a |